Could a cancer drug ease sickle cell pain? early trial launches
NCT ID NCT01245179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety of a drug called panobinostat in 18 adults with sickle cell disease. The drug aims to boost fetal hemoglobin and reduce inflammation, which may help control the disease. Participants take capsules three times a week for 12 weeks, and researchers will monitor for side effects and any improvements in blood counts or quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
panobinostat (a drug taken as capsules three times a week)
What this could lead to
If it works, this could point toward a new treatment option for sickle cell disease that reduces pain crises and hospitalizations.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••